MicroRNA Signature Predicts Molecular Risk Groups in Medulloblastoma
M Remke, AHC Bai, A Pscherer, A Korshunov, P Northcott, M Taylor, P Lichter, A Kulozik, S Pfister · Klinische Pädiatrie · 2009 · Heft 05
Bibliografische Angaben
Zusammenfassung
Medulloblastoma comprises the most common malignant pediatric brain tumor. Current treatment protocols are solely based on clinically defined risk-groups. Identification of novel tumor-derived markers may improve the risk assessment of medulloblastoma patients. Thus, array-CGH or FISH were carried out to determine tumor-specific genomic imbalances associated with overall survival (OS) in 340 medulloblastoma patients. Detection of MYC-/MYCN amplification, Trisomy 6, 17p-loss or 17q-gain was linked to high molecular risk. In contrast, medulloblastomas with Monosomy 6 and balanced copy-number status of 6q, 17p, 17q…
